SomaScan™
Nature Medicine
Semaglutide’s
Proteomic Effects in
Obesity Management
A recent study published in Nature Medicine highlights research conducted by Novo Nordisk using the SomaScan™ Assay to evaluate semaglutide’s effects on approximately 6,400 human proteins.
Drawing on data from nearly 2,000 participants, the study offers valuable insights into how semaglutide impacts metabolic pathways, inflammatory responses and cardiovascular health.
Key findings include:
- Insights into disease mechanisms
- Potential opportunities for drug repurposing
- The importance of monitoring changes in blood proteins with weight loss treatments
Get exclusive access to study updates!
Stay up to date with the latest proteomic studies.
Sign up now to receive more articles
that will help you expand your research.